PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Cerebrolysin: Research & Evidence

Established Evidence

Published research, clinical trial data, and evidence grading for Cerebrolysin across studied indications.

Back to Cerebrolysin overview

Research Summary

Cerebrolysin has one of the largest evidence bases among non-FDA-approved compounds, with 337 human studies, 61 RCTs, and 8+ meta-analyses. Meta-analyses confirm benefit in stroke recovery and vascular dementia, though the pivotal CEREBO trial narrowly missed significance.

Evidence by Indication (4 indications)

Indication Tier Trials Summary
Stroke recovery Tier B 61 Meta-analysis shows mRS 0-1 OR 1.68 (p=0.003); 61 RCTs across stroke indications
Vascular dementia Tier B 15 Meta-analysis shows cognitive function SMD 0.72 (p<0.0001) and improved ADL
Alzheimer's disease Tier C 10 Moderate improvements in cognitive function; mixed results across trials
Traumatic brain injury Tier C 8 Accelerated recovery in moderate TBI; larger confirmatory trials needed

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (12 sources)

  1. 1. Update on Neuroprotection after Traumatic Brain Injury. Study

    (2025), CNS drugs

  2. 2. Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia. Study

    (2025), Molecular biology reports

  3. 3. Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway. Study

    (2025), Molecular brain

  4. 4. Microglial Polarization and Therapeutic Strategies in Post-stroke Neuroinflammation. Study

    (2025), Neurology and therapy

  5. 5. The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. Study

    (2025), Neuroscience

  6. 6. Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. Meta-Analysis

    (2024), Frontiers in pharmacology

  7. 7. Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review. Review

    (2024), Current allergy and asthma reports

  8. 8. Neuroprotective and neuroregenerative drugs after severe traumatic brain injury: A narrative review from a clinical perspective. Review

    (2024), Wiener klinische Wochenschrift

  9. 9. Current neuroprotective agents in stroke. Study

    (2024), Turkish journal of physical medicine and rehabilitation

  10. 10. Environmental enrichment and cerebrolysin improve motor and cognitive performance in a rat model of stroke. Study

    (2024), Brain research

  11. 11. Cerebrolysin for acute ischaemic stroke: a meta-analysis. Meta-Analysis

    (2017), Various

  12. 12. Cerebrolysin in Alzheimer's disease: a systematic review. Review

    (2012), Various